Umeå-based QureTech Bio AB receives support from the Swedish Research Council’s major investment ENABLE-2, which in collaboration with Vinnova gives small and medium-sized companies access to the ENABLE-2 platform to continue development of new antibiotics.
Umeå-based pharmaceutical development company QureTech Bio is hiring more people as it intensifies its work to combat antibiotic resistance.
“We recently received a major investment which has created long-term security in the company. With more people in place, we can now really push on and look to the future”, says Helén Fält, who was recently appointed the new CEO of QureTech Bio.
Umeå-based biotech company QureTech Bio has appointed Helén Fält as its new acting CEO, replacing Fredrik Almqvist, one of the company’s original founders.
“We have recently secured significant new investment and so it feels like the perfect time for Helén to come in and develop our business even further,” says Fredrik Almqvist.